glp 1 agonist retatrutide From Obesity to Metabolic Health: Why Is a Game-Changer Understanding the Next-Gen Weight Loss

Goldman Sachs Research estimates that GLP-1 obesity drug prescriptions could reach 30 million Americans by 2028 if coverage barriers are resolved, representing USD 150+ billion in additional annual market potential beyond current diabetes-only prescribing

10.1007/BF00401145 7

Departments of Agriculture and Health and Human Services | AAFP, accessed April 22, 2025, Healthy diet - World Health Organization (WHO), accessed April 22, 2025, 2015-2020 Dietary Guidelines for Americans - Office of the Assistant Secretary for Health, accessed April 22, 2025, Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss

Neuroepidemiology (2007) 29:12532

This effect appeared to be mediated by antioxidant mechanisms involving GSK3 phosphorylation 156 , and it was also associated with a reduction of measures of memory impairment in mice 157

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial